Cargando…
Therapeutic adherence in hypertension: Current evidence and expert opinion from India
Hypertension (HTN) is a globally prevalent non-communicable disease contributing significantly to cardiovascular (CV) morbidity and mortality. In achieving control of HTN, therapeutic adherence plays a crucial role. Studies from India identify varying rates of adherence to antihypertensive medicatio...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642659/ https://www.ncbi.nlm.nih.gov/pubmed/34861979 http://dx.doi.org/10.1016/j.ihj.2021.09.003 |
_version_ | 1784609712844570624 |
---|---|
author | Dalal, Jamshed J. Kerkar, Prafulla Guha, Santanu Dasbiswas, Arup Sawhney, J.P.S. Natarajan, Sivakadaksham Maddury, Srinivasa Rao Kumar, A. Sreenivas Chandra, Nishith Suryaprakash, Gulla Thomas, Joy M. Juvale, N.I. Sathe, Sunil Khan, Aziz Bansal, Sandeep Kumar, Viveka Reddi, Rajshekhar |
author_facet | Dalal, Jamshed J. Kerkar, Prafulla Guha, Santanu Dasbiswas, Arup Sawhney, J.P.S. Natarajan, Sivakadaksham Maddury, Srinivasa Rao Kumar, A. Sreenivas Chandra, Nishith Suryaprakash, Gulla Thomas, Joy M. Juvale, N.I. Sathe, Sunil Khan, Aziz Bansal, Sandeep Kumar, Viveka Reddi, Rajshekhar |
author_sort | Dalal, Jamshed J. |
collection | PubMed |
description | Hypertension (HTN) is a globally prevalent non-communicable disease contributing significantly to cardiovascular (CV) morbidity and mortality. In achieving control of HTN, therapeutic adherence plays a crucial role. Studies from India identify varying rates of adherence to antihypertensive medications. Multiple factors determine treatment adherence in HTN. In India, factors such as lower socioeconomic status, health literacy, asymptomatic nature of disease, forgetfulness, cost of medications, and duration of HTN determine the adherence. An excellent physician-patient relationship incorporating adequate counseling along with the use of other methods can identify poor adherence. Improving adherence necessitates incorporating a multipronged approach with strategies directed at physicians, patients, and health systems. With innovation in therapeutics, the pharmaceutical sector can contribute significantly to improve adherence. Furthermore, increasing adherence to lifestyle interventions can help achieve better HTN control and improve CV outcomes. In the Indian context, more emphasis is necessary on patient education, enhanced physician-patient relationship and communication, increased access to health care, and affordability in improving therapeutic adherence in HTN. |
format | Online Article Text |
id | pubmed-8642659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86426592022-02-15 Therapeutic adherence in hypertension: Current evidence and expert opinion from India Dalal, Jamshed J. Kerkar, Prafulla Guha, Santanu Dasbiswas, Arup Sawhney, J.P.S. Natarajan, Sivakadaksham Maddury, Srinivasa Rao Kumar, A. Sreenivas Chandra, Nishith Suryaprakash, Gulla Thomas, Joy M. Juvale, N.I. Sathe, Sunil Khan, Aziz Bansal, Sandeep Kumar, Viveka Reddi, Rajshekhar Indian Heart J Review Article Hypertension (HTN) is a globally prevalent non-communicable disease contributing significantly to cardiovascular (CV) morbidity and mortality. In achieving control of HTN, therapeutic adherence plays a crucial role. Studies from India identify varying rates of adherence to antihypertensive medications. Multiple factors determine treatment adherence in HTN. In India, factors such as lower socioeconomic status, health literacy, asymptomatic nature of disease, forgetfulness, cost of medications, and duration of HTN determine the adherence. An excellent physician-patient relationship incorporating adequate counseling along with the use of other methods can identify poor adherence. Improving adherence necessitates incorporating a multipronged approach with strategies directed at physicians, patients, and health systems. With innovation in therapeutics, the pharmaceutical sector can contribute significantly to improve adherence. Furthermore, increasing adherence to lifestyle interventions can help achieve better HTN control and improve CV outcomes. In the Indian context, more emphasis is necessary on patient education, enhanced physician-patient relationship and communication, increased access to health care, and affordability in improving therapeutic adherence in HTN. Elsevier 2021 2021-09-15 /pmc/articles/PMC8642659/ /pubmed/34861979 http://dx.doi.org/10.1016/j.ihj.2021.09.003 Text en © 2021 Cardiological Society of India. Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Dalal, Jamshed J. Kerkar, Prafulla Guha, Santanu Dasbiswas, Arup Sawhney, J.P.S. Natarajan, Sivakadaksham Maddury, Srinivasa Rao Kumar, A. Sreenivas Chandra, Nishith Suryaprakash, Gulla Thomas, Joy M. Juvale, N.I. Sathe, Sunil Khan, Aziz Bansal, Sandeep Kumar, Viveka Reddi, Rajshekhar Therapeutic adherence in hypertension: Current evidence and expert opinion from India |
title | Therapeutic adherence in hypertension: Current evidence and expert opinion from India |
title_full | Therapeutic adherence in hypertension: Current evidence and expert opinion from India |
title_fullStr | Therapeutic adherence in hypertension: Current evidence and expert opinion from India |
title_full_unstemmed | Therapeutic adherence in hypertension: Current evidence and expert opinion from India |
title_short | Therapeutic adherence in hypertension: Current evidence and expert opinion from India |
title_sort | therapeutic adherence in hypertension: current evidence and expert opinion from india |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642659/ https://www.ncbi.nlm.nih.gov/pubmed/34861979 http://dx.doi.org/10.1016/j.ihj.2021.09.003 |
work_keys_str_mv | AT dalaljamshedj therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT kerkarprafulla therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT guhasantanu therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT dasbiswasarup therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT sawhneyjps therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT natarajansivakadaksham therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT maddurysrinivasarao therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT kumarasreenivas therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT chandranishith therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT suryaprakashgulla therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT thomasjoym therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT juvaleni therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT sathesunil therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT khanaziz therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT bansalsandeep therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT kumarviveka therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia AT reddirajshekhar therapeuticadherenceinhypertensioncurrentevidenceandexpertopinionfromindia |